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INTRODUCTION
Despite improvements in plastic surgery, necrosis remains a major complication in the cosmetic use of skin flaps. Its occurrence can have a devastating impact on the envisioned result. Insufficient blood supply to the skin flap and the consequent microcirculation dysfunction are considered to be the dominant causes of necrosis in surgical flaps 1, 2 . Different vasoactive drugs have been tested, with varying degrees of success, on improving localized ischemia, and a standard reference drug for the pharmacological treatment of tissue ischemia has not been identified to date [3] [4] [5] .
Buflomedil has been clinically used to treat peripheral circulatory deficits. Previously published studies have indicated that this drug decreases peripheral vascular resistance resulting in increased blood perfusion [6] [7] [8] .
Phosphodiesterase (PDE) inhibitors have also been studied for their vasodilating effects. PDEs are a group of related enzymes, comprised of 11 subtypes, that cleave c-AMP (cyclic adenosine monophosphate) and/or c-GMP (cyclic guanosine monophosphate), inactivating it. Sildenafil is a type 5 PDE inhibitor, which acts specifically on c-GMP molecules abundant in smooth muscle cells such as those found in vessel walls 5, 9 . When endothelial cells release nitric oxide, it diffuses into the smooth muscle cells of the microvasculature and binds guanylate cyclase, activating it and leading to the formation of c-GMP 10 . c-GMP, in turn, acts to relax myosin (a protein in the vessel walls), resulting in vessel dilation. Thus, sildenafil's inhibition of the enzyme that cleaves c-GMP would be expected to result in an increased concentration of c-GMP, with consequent vasodilation 5,9 . This study aimed to assess the impact of buflomedil and sildenafil on tissue viability in randomized skin flaps.
METHODS
Thirty adult, male, Wistar rats weighing 250-280 g were used in this study. The animals were kept in the climate controlled animal laboratory of Instituto de Cirurgia Plástica Santa Cruz (São Paulo, SP, Brazil), with water and feed ad libitum, for one week prior to the study. Animals were treated in accordance to the resolutions of the Brazilian Association of Animal Experimentation (COBEA).
Anesthesia was induced by intraperitoneal administration of a mixture of ketamine (100 mg/ml) and xylazine (20 mg/ ml) at a total dose of 0.2 ml per 100 mg of body weight. The backs of the animals were shaved and cleaned with an antiseptic. Thereafter, a skin flap with a caudal pedicle (10 x 3 cm) was made on the back of each animal with sterile instruments; the iliac crests served as anatomical reference points for the beginning of each flap (Figure 1 ). The flap was elevated above the panniculus carnosus and then continuously resutured to the wound bed using 4-0 monofilament nylon. The flaps were sutured in place on the wound bed with markings placed every 2 cm along the flap length in order to facilitate observation of the necrotic area (Figures 1 and 2) .
The animals were randomly divided into three groups, with 10 animals in each group: control group, to which only the vehicle solution was administered; sildenafil group, to which a solution containing sildenafil was administered; and buflomedil group, to which a solution containing buflomedil was administered.
The suspensions were previously prepared in a laboratory and the drug vehicle consisted of a 1:1 mixture of 1% carboxymethylcellulose and a simple syrup, prepared according to the Brazilian Pharmacopoeia IV-4 th ed. (1988) . Seven bottles containing 300 mL of the vehicle were prepared. Four bottles were used in the preparation of the suspensions, as described below, and three were reserved for the control group.
The sildenafil suspension was prepared by grinding 30 Viagra® tablets (50 mg) into a fine powder, which was suspended in the above-mentioned vehicle to form a paste. The paste was subsequently mixed with 1% carboxymethylcellulose and simple syrup in a test tube to obtain a final volume of 600 mL (2.5 mg/mL, final concentration) and stored in two opaque plastic bottles (300 mL/bottle). The buflomedil suspension was prepared by mixing a fine powder of 5 tablets of Bufedil® 300 mg with the base vehicle of a 1:1 mixture of 1% carboxymethylcellulose and a simple syrup to form a paste. This paste was transferred to a test tube, and the volume was made up to 600 mL to obtain a concentration of 2.5 mg/mL. The suspension was then transferred to two opaque plastic bottles of 300 mL each.
The solutions were administered by oral gavage. The first dose was administered in the immediate postoperative period and the remaining doses were administered once a day, for 7 days. The daily dose of sildenafil and buflomedil was 10 mg/kg, with an equivalent volume of vehicle administered to the control group animals.
Post-surgery, the animals were kept in individual cages and the flaps were observed and photographed for seven days. At the end of this period, the rats were sacrificed. The viable area of the flap was designed and transposed to a paper carton (Figure 2) , which was scanned and analyzed using Image Tool 2.0 ® , a specific software designed for area calculation.
The flaps were cleaved and fixed in 10% formalin and a tissue slice, representing the viable area, was processed in a gradient of alcohol and xylene solutions. The dehydrated tissue was embedded in paraffin, sectioned (4 µm thick) and stained with hematoxylin and eosin. The images were scanned and the vessel diameters were calculated using Image Tool 2.0 ® .
The results were statistically analyzed using the Kruskal-Wallis test.
RESULTS
The average viable areas of the flaps from each group were 16.2 + 3.56 cm² (control group), 17.69 + 2.54 cm² (buflomedil group), and 18.28 + 3.74 cm² (sildenafil group) (Tables 1 and 2, Figure 3 ). Data analysis showed no statistically significant difference among the three groups (H = 1.6475; degrees of freedom = 2; P = 0.4388).
The average vessel diameter observed in flaps from the buflomedil group was 38.35 µm (median = 34.25 µm; standard deviation = 19.85); from the control group, 27.1 µm (median = 24.75 µm; standard deviation = 12.8); and from the sildenafil group, 19.9 µm (median = 18.5 µm; standard deviation = 6.99). Statistical analysis indicated a statistical difference in at least one of the groups (P = 0.02); the post-test, using the method of Dunn's multiple comparisons, revealed significant differences between the buflomedil and sildenafil groups, without a significant difference between either treatment group and the control groups (Figure 4) .
DISCUSSION
The data demonstrated that buflomedil's reported beneficial effect on microcirculation was not correlated with a reduction in ischemia in tissue flaps. However, some studies have shown conflicting results 3, 6, 7, 11 . The studies that reported reduced tissue ischemia tested buflomedil at a dose of 3 mg/ kg, intraperitoneally 6, 7 or intravenously 3, 8 . As the oral route was used in this study, a higher dose (10 mg/kg) of drug was administered to account for potentially poor absorption from the gastrointestinal tract. In humans, it is known that only approximately 30% of the drug is absorbed through the gastrointestinal tract. Therefore, although doses of 50-200 mg/ day are recommended when dosed intravenously, those doses are increased to 300-600 mg/day when administered orally 12 .
The ineffectiveness of buflomedil in this study was not unprecedented. A study conducted by Quirinia et al. 4 indicated the failure of this drug to increase flap viability in rats at doses of 10 mg/kg using the intraperitoneal route. The efficacy of this drug for other applications (e.g., the treatment of intermittent claudication) is currently being questioned due to conflicting published results 13 .
Sildenafil, however, is a drug with vasodilating effects that could potentially benefit randomized flaps. Although sildenafil still has been infrequently evaluated for this indication, two relatively recent studies have suggested some degree of randomized flap viability improvement in rats 5, 9 . However, in the study of Hart et al. 5 , the action of the drug throughout the postoperative period was followed and the observed improvement in tissue viability on the third postoperative day did not remain statistically different, relative to the control group, through the fifth and seventh days. Although the administration route and dosages were similar to these studies, a significant improvement in the area of flap necrosis was not evidenced, compared to the control and buflomedil groups.
